Behçet Disease: A Comprehensive Medical Overview

What is Behçet Disease?

Behçet disease (ORPHA: 117) is a rare, chronic autoimmune vasculitis that causes inflammation of blood vessels throughout the body. This multi-system disorder primarily affects young adults between 20-40 years old and is characterized by recurrent painful mouth ulcers, genital ulcers, eye inflammation, and skin lesions. The condition follows a relapsing-remitting course with unpredictable flares and periods of remission. Behçet disease is most common along the ancient Silk Road, particularly in Turkey, the Middle East, and parts of Asia, though it occurs worldwide.

Key statistics

Symptoms

**Common symptoms include:** Recurrent mouth ulcers, genital ulcers, skin lesions, eye inflammation, joint pain, fatigue, and fever during flares.

**Oral symptoms:** Nearly all patients (95-100%) develop painful, round or oval mouth ulcers with yellow-white centers and red borders. These aphthous ulcers typically appear on the tongue, lips, gums, and inside the cheeks, often recurring every few weeks.

**Genital manifestations:** Painful genital ulcers affect 60-90% of patients, appearing on the scrotum, penis, vulva, or vagina. These ulcers are typically deeper than oral lesions and may leave scars.

Submit Your Paper

**Skin involvement:** Various skin lesions occur in 60-70% of patients, including acne-like pustules, erythema nodosum (painful red nodules), and pathergy (abnormal skin reaction to minor trauma like needle pricks).

**Ocular complications:** Eye involvement affects 30-70% of patients and represents the most serious manifestation. Symptoms include anterior uveitis, posterior uveitis, retinal vasculitis, and potential vision loss if untreated.

**Joint symptoms:** Arthritis affects 40-60% of patients, typically involving knees, ankles, and wrists with pain and swelling but usually no permanent joint damage.

**Vascular manifestations:** Thrombophlebitis, deep vein thrombosis, and arterial involvement occur in 10-30% of cases, potentially affecting any blood vessel.

**Neurological involvement:** Central nervous system complications develop in 5-15% of patients, including headaches, confusion, stroke-like symptoms, and cognitive changes.

Causes and risk factors

The exact cause of Behçet disease remains unknown, but research points to a combination of genetic predisposition, environmental triggers, and immune system dysfunction. The strongest genetic association involves the HLA-B51 allele, found in 40-80% of patients compared to 0-15% of the general population in endemic areas.

**Genetic factors:** Multiple genes contribute to disease susceptibility, including variations in immune system genes like IL10, IL23R, and TNFAIP3. However, no single gene causes the disease, indicating complex genetic inheritance.

**Environmental triggers:** Infectious agents, particularly certain streptococcal bacteria and herpes simplex virus, may trigger disease onset in genetically susceptible individuals. Stress, trauma, and hormonal changes can also precipitate flares.

**Immune dysfunction:** The disease involves both innate and adaptive immune system abnormalities, leading to excessive inflammation and blood vessel damage.

**Geographic risk factors:** Highest prevalence occurs in countries along the historic Silk Road, including Turkey, Iran, Japan, Korea, and parts of the Mediterranean region.

Prevention

Currently, there is no known way to prevent Behçet disease due to its complex genetic and environmental causes. However, early recognition of symptoms and prompt medical evaluation can help prevent serious complications, particularly vision-threatening eye involvement. Individuals with a family history of the condition or those from high-prevalence geographic regions should be aware of characteristic symptoms and seek medical attention if they develop recurrent oral ulcers combined with other manifestations.

Complications

Without proper treatment, Behçet disease can lead to severe, life-threatening complications. Ocular involvement represents the most serious concern, potentially progressing to blindness in 10-20% of affected patients. Vascular complications include venous thrombosis, arterial aneurysms, and pulmonary artery involvement, which can be fatal.

Neurological complications, though less common, can cause permanent cognitive impairment, paralysis, or death. Gastrointestinal involvement may lead to intestinal perforation and bleeding. The chronic, unpredictable nature of the disease often results in significant psychological impact, including depression and anxiety. Joint involvement, while typically non-destructive, can cause chronic pain and functional limitations.

Diagnosis

No single laboratory test can diagnose Behçet disease. Diagnosis relies primarily on clinical criteria, most commonly the International Study Group (ISG) criteria, which require recurrent oral ulceration plus two of the following: recurrent genital ulceration, eye lesions, skin lesions, or positive pathergy test.

**Clinical assessments:** Comprehensive physical examination, detailed medical history, and documentation of symptom patterns over time.

**Pathergy test:** A skin test involving needle prick that shows abnormal inflammatory response in 40-70% of patients, though sensitivity varies by geographic region.

**Laboratory tests:** No specific diagnostic blood tests exist, but testing may include inflammatory markers (ESR, CRP), complete blood count, and HLA-B51 typing for additional support.

**Imaging studies:** MRI or CT scans may be needed to evaluate vascular, neurological, or gastrointestinal involvement.

**Ophthalmologic examination:** Essential for detecting eye involvement, including fundoscopy and specialized imaging.

**Tissue biopsy:** May be performed on skin lesions to rule out other conditions, though findings are not specific for Behçet disease.

Treatment

Treatment focuses on controlling inflammation, preventing flares, and managing specific organ involvement. Therapeutic approaches vary based on disease severity and affected organs.

**Topical treatments:** Corticosteroids for mouth and genital ulcers, along with topical anesthetics for pain relief.

**Systemic medications:** Colchicine serves as first-line therapy for mucocutaneous manifestations. Azathioprine is commonly used for maintenance therapy and eye involvement.

**Immunosuppressive drugs:** Methotrexate, Cyclosporine, and Mycophenolate mofetil may be used for moderate to severe disease.

**Biologic therapies:** Infliximab, Adalimumab, and Interferon alfa-2a are reserved for severe, refractory cases, particularly those with eye or vascular involvement.

**Corticosteroids:** Prednisolone may be used for acute flares but is avoided for long-term use due to side effects.

**Symptomatic treatments:** Pain medications, anticoagulants for thrombosis, and specific treatments for neurological or gastrointestinal complications.

Prognosis

The prognosis for Behçet disease varies significantly based on organ involvement, with eye, vascular, and neurological manifestations indicating more serious disease. With appropriate treatment, most patients can achieve good disease control and maintain normal life expectancy. However, approximately 10-20% of patients with eye involvement may experience significant vision loss despite treatment.

Males tend to have more severe disease, particularly in Mediterranean populations, while females often have better outcomes. Young age of onset and the presence of HLA-B51 may indicate more aggressive disease. The condition typically shows improvement over time, with many patients experiencing fewer and less severe flares after the first decade of disease.

Quality of life can be significantly impacted during active disease periods, but appropriate treatment and disease management can help patients maintain normal activities and relationships.

Quality of life

Living with Behçet disease requires adapting to unpredictable flares while maintaining overall health and well-being. Stress management techniques, including meditation, yoga, and regular exercise, can help reduce flare frequency and severity. A balanced diet rich in anti-inflammatory foods may provide additional benefits.

Regular sleep patterns and avoiding known triggers can help prevent flares. Patients should maintain good oral hygiene and avoid trauma to the mouth when possible. Sun protection is important for those with skin involvement.

Mental health support is crucial, as chronic illness can lead to depression and anxiety. Joining patient support groups and connecting with others who have the condition can provide valuable emotional support and practical advice.

Workplace accommodations may be necessary during flares, including flexible schedules and ergonomic considerations. Open communication with employers about the condition can help ensure appropriate support.

Pregnancy and fertility

Behçet disease generally does not significantly impact fertility in either men or women. Pregnancy outcomes are typically favorable, with many women experiencing improvement in disease activity during pregnancy due to hormonal changes. However, some may experience flares postpartum.

Medication management during pregnancy requires careful consideration. Colchicine and Azathioprine are generally considered safe during pregnancy, while other immunosuppressive drugs may need to be discontinued or modified.

Genetic counseling may be beneficial for couples concerned about passing the condition to their children, though the inheritance pattern is complex and the risk is generally low. Close monitoring by both rheumatology and obstetric specialists is recommended throughout pregnancy and the postpartum period.

Children

Behçet disease in children is rare but follows similar patterns to adult disease, with some important differences. Pediatric patients more commonly present with fever, headache, and behavioral changes. Eye involvement may be less common but equally serious when it occurs.

Growth and development are typically normal unless systemic inflammation is poorly controlled. School accommodations may be necessary during flares, including modified schedules and physical education restrictions.

Medication dosing requires careful adjustment for pediatric patients, and long-term growth monitoring is important when using corticosteroids or other immunosuppressive drugs. Transition to adult care should be planned carefully, typically occurring in the late teenage years with gradual transfer of responsibility for disease management.

When to see a doctor

Immediate medical attention is required for sudden vision changes, severe headache with neurological symptoms, chest pain, difficulty breathing, or signs of stroke. These may indicate serious complications requiring emergency treatment.

Routine medical care should be sought for recurrent mouth ulcers, especially when accompanied by genital ulcers, skin lesions, or joint pain. Early diagnosis and treatment can prevent serious complications.

Regular ophthalmologic examinations are essential for all patients, even those without eye symptoms, as inflammation can be silent in early stages. Any new or worsening symptoms should prompt medical evaluation to adjust treatment as needed.

Regional context

While Behçet disease is less common in the Caucasus region compared to Turkey and the Middle East, cases do occur, particularly given the geographic proximity to high-prevalence areas. The HLA-B51 allele frequency in Georgian, Armenian, and Azerbaijani populations may influence regional disease patterns, though specific prevalence data is limited. Healthcare providers in the region should maintain awareness of the condition, particularly when evaluating patients with recurrent oral ulcers and multi-system symptoms. GMJ welcomes contributions from regional researchers to build the evidence base for Behçet disease in the Caucasus.

Research and clinical trials

Current research focuses on understanding genetic susceptibility, developing targeted therapies, and improving quality of life measures. Studies are investigating new biologic medications, including secukinumab and ustekinumab, for treatment-resistant cases.

Genetic research aims to identify additional susceptibility genes and develop personalized treatment approaches. Biomarker studies seek to develop blood tests for monitoring disease activity and predicting flares.

Clinical trials are ongoing for various therapeutic approaches, including stem cell therapy and novel immunomodulatory drugs. Patients interested in clinical trials can search ClinicalTrials.gov for current opportunities.

Frequently asked questions

Is Behçet disease contagious?

No, Behçet disease is not contagious. It is an autoimmune condition that cannot be transmitted from person to person through contact, air, or other means.

Will I pass Behçet disease to my children?

While there is a genetic component to Behçet disease, it does not follow simple inheritance patterns. The risk of passing the condition to children is low, and having a parent with the disease does not guarantee a child will develop it.

Can diet affect Behçet disease symptoms?

While no specific diet has been proven to treat Behçet disease, some patients report that certain foods may trigger flares. Maintaining a healthy, balanced diet and avoiding personal trigger foods may help with overall management.

How long do flares typically last?

Flare duration varies significantly among patients and can range from days to weeks. With appropriate treatment, most flares can be shortened and made less severe.

Can Behçet disease be cured?

Currently, there is no cure for Behçet disease. However, the condition can be effectively managed with appropriate medications, and many patients achieve long periods of remission with minimal symptoms.

Support and resources

**International Behçet’s Disease Association (IBDA):** Provides patient education and support resources (behcetdiseasesociety.org)

**American Behçet’s Disease Association:** Offers information and patient support services (behcets.com)

**Orphanet:** Comprehensive rare disease information portal (orpha.net)

**European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA):** Provides expert guidance and resources

**National Organization for Rare Disorders (NORD):** Patient advocacy and research support (rarediseases.org)

**Behçet’s Syndrome Society (UK):** Patient support and information services (behcets.org.uk)

Related conditions

Systemic lupus erythematosus – Another autoimmune condition that can cause multi-system inflammation and shares some clinical features with Behçet disease.

Inflammatory bowel disease – Can cause similar gastrointestinal symptoms and is sometimes difficult to distinguish from intestinal Behçet disease.

Herpes simplex virus infection – Can cause recurrent oral and genital ulcers that may be confused with Behçet disease manifestations.

Recurrent aphthous stomatitis – Causes recurrent mouth ulcers similar to those seen in Behçet disease but without other systemic features.

Other vasculitides – Various forms of blood vessel inflammation that can mimic certain aspects of Behçet disease, particularly vascular manifestations.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, UpToDate, relevant EULAR/ACR/WHO guidelines. This article is for informational purposes only and does not constitute medical advice. Content licensed under CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.